1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014

Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Neuroendocrine Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Neuroendocrine Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Neuroendocrine Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Neuroendocrine Cancer 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Neuroendocrine Cancer Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Neuroendocrine Cancer 33
Apr 09, 2013: ArQule's New AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase I Trial 33
Oct 25, 2008: Callisto Pharmaceuticals To Open Atiprimod Phase II Extension Trial In Neuroendocrine Cancer 33
Oct 07, 2008: Neotropix Announces The Expansion Of On-going Clinical Trial For Adult Neuroendocrine Cancers 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
Pfizer Inc. 38
Clinical Trial Overview of Pfizer Inc. 38
Ipsen S.A. 39
Clinical Trial Overview of Ipsen S.A. 39
F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 40
Progenics Pharmaceuticals, Inc. 41
Clinical Trial Overview of Progenics Pharmaceuticals, Inc. 41
Tekmira Pharmaceuticals Corp. 42
Clinical Trial Overview of Tekmira Pharmaceuticals Corp. 42
Threshold Pharmaceuticals, Inc. 43
Clinical Trial Overview of Threshold Pharmaceuticals, Inc. 43
Merck and Co., Inc. 44
Clinical Trial Overview of Merck and Co., Inc. 44
Eli Lilly and Company 45
Clinical Trial Overview of Eli Lilly and Company 45
Daiichi Sankyo Company, Limited 46
Clinical Trial Overview of Daiichi Sankyo Company, Limited 46
Clinical Trial Overview of Top Institutes / Government 47
National Cancer Institute 47
Clinical Trial Overview of National Cancer Institute 47
The University of Texas M. D. Anderson Cancer Center 49
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 49
Memorial Sloan Kettering Cancer Center 50
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 50
Stanford University 51
Clinical Trial Overview of Stanford University 51
Grupo Espanol de Tumores Neuroendocrinos 52
Clinical Trial Overview of Grupo Espanol de Tumores Neuroendocrinos 52
University of Wisconsin Madison 53
Clinical Trial Overview of University of Wisconsin Madison 53
The University of Iowa 54
Clinical Trial Overview of The University of Iowa 54
University of California, San Francisco 55
Clinical Trial Overview of University of California, San Francisco 55
Alberta Health Services 56
Clinical Trial Overview of Alberta Health Services 56
Five Key Clinical Profiles 57
Appendix 121
Abbreviations 121
Definitions 121
Research Methodology 122
Secondary Research 122
About GlobalData 123
Contact Us 123
Disclaimer 123
Source 124

List of Tables
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Neuroendocrine Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Neuroendocrine Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Neuroendocrine Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Neuroendocrine Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Neuroendocrine Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Neuroendocrine Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Neuroendocrine Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Neuroendocrine Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Neuroendocrine Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Neuroendocrine Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Neuroendocrine Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Neuroendocrine Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Neuroendocrine Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Neuroendocrine Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Neuroendocrine Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 35
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 38
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014* 39
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 40
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Progenics Pharmaceuticals, Inc., 2014* 41
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Tekmira Pharmaceuticals Corp., 2014* 42
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Threshold Pharmaceuticals, Inc., 2014* 43
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 44
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 45
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 46
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 47
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 49
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 50
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 51
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Grupo Espanol de Tumores Neuroendocrinos, 2014* 52
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Wisconsin Madison, 2014* 53
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Iowa, 2014* 54
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 55
Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Alberta Health Services, 2014* 56

List of Figures
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Neuroendocrine Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Neuroendocrine Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Neuroendocrine Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Neuroendocrine Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Neuroendocrine Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Neuroendocrine Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Neuroendocrine Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Neuroendocrine Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Neuroendocrine Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Neuroendocrine Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Neuroendocrine Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Neuroendocrine Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 122

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.